A clinical trial of MRTX849 in combination with with a CDK4/6 inhibitor (palbociclib) in patients with a CDK4 amplification in 2nd or 3rd line NSCLC
Latest Information Update: 12 Aug 2020
At a glance
- Drugs Adagrasib (Primary) ; Palbociclib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Mirati Therapeutics
- 12 Aug 2020 New trial record
- 06 Aug 2020 According to a Mirati Therapeutics media release, the company plans to initiate this study later in 2020.